Camptosar Reduced Starting Dose Recommended In Patients With Genetic Marker
This article was originally published in The Pink Sheet Daily
Executive Summary
Patients with the deficiency of a metabolizing enzyme have an increased risk of neutropenia, revised labeling for Pfizer’s oncologic says. Patients with the deficiency should start at a lower dose, though the appropriate starting dose is not known, FDA says.
You may also be interested in...
Camptosar Genetic Test Launched By Genzyme
Invader assay identifies deficient UGT1A1*28 allele, which increases risk of neutropenia in colorectal cancer patients taking Camptosar.
Camptosar Genetic Test Launched By Genzyme
Invader assay identifies deficient UGT1A1*28 allele, which increases risk of neutropenia in colorectal cancer patients taking Camptosar.
Pharmacogenetic Data Integration Into Labeling To Be Discussed By Subcommittee
Clinical Pharmacology Subcommittee will meet Nov. 14-15 on several topics including pharmacogenetic data integration and the biomarker-surrogate endpoint project of FDA's "Critical Path" initiative.